Clinical information of ATL patients
| . | CNA (n = 463) . | Mutation (n = 414) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Sex | ||||
| Male | 245 | 53 | 218 | 53 |
| Female | 218 | 47 | 196 | 47 |
| Subtype | ||||
| Acute | 224 | 48 | 222 | 54 |
| Lymphoma | 104 | 22 | 73 | 18 |
| Chronic | 105 | 23 | 99 | 24 |
| Smoldering | 30 | 6 | 20 | 5 |
| Age | ||||
| <70 y | 249 | 54 | 244 | 59 |
| ≥70 y | 88 | 19 | 88 | 21 |
| Not available | 126 | 27 | 82 | 20 |
| . | CNA (n = 463) . | Mutation (n = 414) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Sex | ||||
| Male | 245 | 53 | 218 | 53 |
| Female | 218 | 47 | 196 | 47 |
| Subtype | ||||
| Acute | 224 | 48 | 222 | 54 |
| Lymphoma | 104 | 22 | 73 | 18 |
| Chronic | 105 | 23 | 99 | 24 |
| Smoldering | 30 | 6 | 20 | 5 |
| Age | ||||
| <70 y | 249 | 54 | 244 | 59 |
| ≥70 y | 88 | 19 | 88 | 21 |
| Not available | 126 | 27 | 82 | 20 |
| . | Survival (n = 226) . | |||
|---|---|---|---|---|
| Aggressive subtypes (n = 152) . | Indolent subtypes (n = 74) . | |||
| n . | % . | n . | % . | |
| Sex | ||||
| Male | 83 | 55 | 30 | 41 |
| Female | 69 | 45 | 44 | 59 |
| Subtype | ||||
| Acute | 125 | 82 | — | — |
| Lymphoma | 27 | 18 | — | — |
| Chronic | — | — | 59 | 80 |
| Smoldering | — | — | 15 | 20 |
| Age | ||||
| <70 y | 107 | 70 | 55 | 74 |
| ≥70 y | 45 | 30 | 19 | 26 |
| Treatment | ||||
| CHOP/CHOP-like | 72 | 47 | — | — |
| VCAP-AMP-VECP | 61 | 40 | — | — |
| Others | 15 | 10 | — | — |
| Not available | 4 | 3 | — | — |
| HSCT during follow-up | ||||
| (–) | 119 | 78 | 59 | 80 |
| (+) | 33 | 22 | 15 | 20 |
| Anti-CCR4 antibody during follow-up | ||||
| (–) | 119 | 78 | 62 | 84 |
| (+) | 33 | 22 | 12 | 16 |
| High calcium (≥2.75 mmol/L) | ||||
| (–) | 125 | 82 | — | — |
| (+) | 27 | 18 | — | — |
| Performance status | — | — | ||
| 0-1 | 92 | 61 | — | — |
| 2-4 | 60 | 39 | — | — |
| JCOG-PI | — | — | ||
| Moderate-risk | 84 | 55 | — | — |
| High-risk | 68 | 45 | — | — |
| Low albumin (<LLN) | ||||
| (–) | — | — | 61 | 82 |
| (+) | — | — | 13 | 18 |
| High BUN (>ULN) | — | — | ||
| (–) | — | — | 71 | 96 |
| (+) | — | — | 3 | 4 |
| High LDH (>ULN) | — | — | ||
| (–) | — | — | 36 | 49 |
| (+) | — | — | 38 | 51 |
| Unfavorable factor | — | — | ||
| (–) | — | — | 30 | 41 |
| (+) | — | — | 44 | 59 |
| . | Survival (n = 226) . | |||
|---|---|---|---|---|
| Aggressive subtypes (n = 152) . | Indolent subtypes (n = 74) . | |||
| n . | % . | n . | % . | |
| Sex | ||||
| Male | 83 | 55 | 30 | 41 |
| Female | 69 | 45 | 44 | 59 |
| Subtype | ||||
| Acute | 125 | 82 | — | — |
| Lymphoma | 27 | 18 | — | — |
| Chronic | — | — | 59 | 80 |
| Smoldering | — | — | 15 | 20 |
| Age | ||||
| <70 y | 107 | 70 | 55 | 74 |
| ≥70 y | 45 | 30 | 19 | 26 |
| Treatment | ||||
| CHOP/CHOP-like | 72 | 47 | — | — |
| VCAP-AMP-VECP | 61 | 40 | — | — |
| Others | 15 | 10 | — | — |
| Not available | 4 | 3 | — | — |
| HSCT during follow-up | ||||
| (–) | 119 | 78 | 59 | 80 |
| (+) | 33 | 22 | 15 | 20 |
| Anti-CCR4 antibody during follow-up | ||||
| (–) | 119 | 78 | 62 | 84 |
| (+) | 33 | 22 | 12 | 16 |
| High calcium (≥2.75 mmol/L) | ||||
| (–) | 125 | 82 | — | — |
| (+) | 27 | 18 | — | — |
| Performance status | — | — | ||
| 0-1 | 92 | 61 | — | — |
| 2-4 | 60 | 39 | — | — |
| JCOG-PI | — | — | ||
| Moderate-risk | 84 | 55 | — | — |
| High-risk | 68 | 45 | — | — |
| Low albumin (<LLN) | ||||
| (–) | — | — | 61 | 82 |
| (+) | — | — | 13 | 18 |
| High BUN (>ULN) | — | — | ||
| (–) | — | — | 71 | 96 |
| (+) | — | — | 3 | 4 |
| High LDH (>ULN) | — | — | ||
| (–) | — | — | 36 | 49 |
| (+) | — | — | 38 | 51 |
| Unfavorable factor | — | — | ||
| (–) | — | — | 30 | 41 |
| (+) | — | — | 44 | 59 |
Clinical information of ATL patients, for which CNA, mutation, and survival data were available. JCOG-PI high-risk was defined as having high a calcium level and/or poor performance status. Unfavorable factor (+) was defined as having any of 3 clinical factors: low albumin, high BUN, and high LDH levels.
AMP, doxorubicin, ranimustine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; LLN, lower limit of normal; ULN, upper limit of normal; VCAP, vincristine, cyclophosphamide, doxorubicin, and prednisone; VECP, vindesine, etoposide, carboplatin, and prednisone.